Therapoid Logo

News

Open Therapeutics and IPwe Form an Intellectual Property Partnership.

Published on: September 14th, 2022

Through a partnership to enhance the licensing of intellectual properties, the companies will work to jointly encourage the licensing of IP portfolios

Cincinnati, OH, and Paris, France — September 14th, 2022 — Open Therapeutics, an open science company, and IPwe, a global platform leveraging the power of artificial intelligence, predictive analytics, and blockchain technology around smart intangible asset management, announce their collaboration to jointly advance the licensing of intellectual property.

therapoid

Open Therapeutics' mission is to enable the global research community to positively impact human, animal, plant, and global environmental health. Its blockchain-based Therapoid.net open science and open access platform is freely provided to the public, researchers, and students. The Therapoid ecosystem provides grant funding, intellectual properties, discussion forums, manuscript review tools, lab equipment, and ScienceCoins cryptocurrency awards when students and scientists collaborate.

IPwe's mission is to promote and encourage innovation with cutting-edge technology based on proven methods so business leaders can better manage intangible assets. Accordingly, the IPwe team has an outstanding reputation in patent monetization due to their combined decades of experience. IPwe's technology and expert team discovered that many of Open Therapeutics' clients' patents have patent monetization potential and are providing Open Therapeutics' clients with access to IPwe's artificial intelligence and blockchain-powered products to drive innovation further.

IPwe's Senior Innovation Director Harry Stacpoole stated, "Over 80% of Open Therapeutics' clients' patents are currently not being licensed despite having potential opportunities for patent monetization. Through our partnership with Open Therapeutics, we can offer their member companies, governments, academic and research institutions the chance to license their unused patents while advancing on our own mission to encourage innovation by providing a mechanism for them to do so".

According to Open Therapeutics Founder Jason E. Barkeloo, "I am proud to work with IPwe to enhance the value of IP assets by increasing transparency with clear and verifiable metrics, particularly for current patents that are unlicensed. Due to our unique IP licensing model that uses an enhanced Creative Commons 4.0 ShareAlike (CC4.0 ShareAlike) agreement, we can help patent holders worldwide enhance the value of their IP assets, especially for those without success previously licensing them. I am so excited about this partnership that for those Therapoid users who also register at IPwe, they will gain a complimentary award of ScienceCoins!"

Further, IPwe will encourage researchers and students seeking academic, government, and corporate career positions to freely join Therapoid. Additionally, IPwe's partnership with Therapoid will provide another avenue for IPwe to encourage innovation by providing the Therapoid global scientific community with a resource to identify which of their patents would best benefit businesses, governments, academic institutions, and society in general.

Similarly, Open Therapeutics, through its IPwe referral program partnership, will encourage its community members and IP providers to join and create IPwe Smart Pools as Founders by contributing the right to license to Smart Pools. This partnership will allow the Therapoid community to advance and deploy technologies based upon patents through the assistance of the IPwe Smart Pools.

As pioneers in decentralized science (DeSci), artificial intelligence, blockchain, non-fungible tokens (NFTs), open access, and open science, Open Therapeutics and IPwe are well positioned to further the convergence of these related technologies and methodologies. Both companies can accelerate an innovative patent license model through this combination while achieving positive social outcomes.

About IPwe

Founded in 2018, IPwe is a global platform leveraging the power of artificial intelligence, predictive analytics, and blockchain technology around smart intangible asset management. IPwe is expanding traditional IP markets by increasing transparency with clear and verifiable metrics to lower costs and enhance value and returns. Through IPwe, everyone from startups to large enterprises, business, and financial executives to IP experts, can collaborate on a business, technical, legal, or financial level to enhance efficiency, value, opportunities, and innovation to better manage their intangible assets.

Press Contact:
Mia Mixan
Head of Marketing
mia@ipwe.com
https://ipwe.com

About Open Therapeutics

The Company freely provides the scientific community the Therapoid™ platform; an open science and open access collaboration ecosystem that puts scientists and students at the center of research for positively impacting human, animal, plant, and global environmental health. Therapoid freely provides intellectual properties (IP), copyrights, grant funding, free equipment, discussion forums, manuscript review tool, knowledge content center, career, and academic opportunities, ScienceCoins cryptocurrency awards, and non-fungible tokens (NFTs). All knowledge is freely provided under a comprehensively modified Creative Commons 4.0 ShareAlike (CC4.0 ShareAlike) license. The use of the Polygon layer 2 on the Ethereum blockchain has provided the Company with the opportunity to lead the development of DeSci dApps and develop Therapoid as a decentralized autonomous organization (DAO). Through creating the world’s biggest think tank, members who openly share can be seen by employment and student recruiters for career, job, and gig opportunities. Therapoid can be particularly beneficial to those in economically developing areas of Africa, Asia, and Latin America.

Media Contact:
Jason E. Barkeloo, Founder/Chair Open Therapeutics

https://Therapoid.net
Info@OpenTherapeutics.org
Twitter: twitter.com/OpenTherapeutic
LinkedIn: www.linkedin.com/company/10851290
Telegram: https://t.me/Therapoid

Open Therapeutics to Exhibit at the American Society of Gene & Cell Therapy (ASGCT) Annual Conference, 15-19 May, 2022, Washington, DC.

Published on: May 18, 2022
 

Download as PDF

Providing Information about the Open Therapeutics’ Therapoid Open Science Platform.

Cincinnati, OH — May 16th, 2022 — Open Therapeutics, an open science company, announces its Chair and interim CEO, Jason E. Barkeloo, will lead a the Open Therapeutics booth exhibit at the American Society of Gene & Cell Therapy (ASGCT) conference at the Walter E. Washington Convention Center, 801 Mt. Vernon Pl NW, Washington DC.

therapoid
 

The Company is also proud to announce its advisor, Timothy Cripe, MD, PhD, will present Drug Modulation of the Myeloid Tumor Microenvironment to Enable Oncolytic HSV Immunotherapy, 850am, May 15th.

The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies.

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

Open Therapeutics’ mission is enabling the global research community to positively impact human, animal, plant, and global environmental health. Therapoid.net is its free open science platform for the public, researchers, and students. It provides grant funding, free equipment, technologies, intellectual properties, forums, preprint server manuscript review tool, and ScienceCoins cryptocurrency awards.

As scientists and students collaborate within the free Therapoid scientific platform, they gain ScienceCoins awards. One might think of ScienceCoins as “Bitcoin for scientists.” For a limited time, when students and researchers freely register, they gain complimentary ScienceCoins*. According to Open Therapeutics founder, Jason E. Barkeloo, “I am proud to represent Open Therapeutics in its leadership of open science at this important conference. This is the first of many conferences we will present and advocate for the adoption of open science and our marquee platform, Therapoid.”

* The complimentary ScienceCoins awards are available for only a limited time and are open to any qualified registrant.

Amsterdam ETHAmsterdam news release

Published on: April 11, 2022
 

Download as PDF

Open Therapeutics Chair and CEO to Lead Decentralized Science (DeSci) and Open Science Panel at Devconnect Week, Amsterdam, Neatherlands, Wednesday, April 20, 2022.

The Potential Impact of Decentralized Autonomous Organizations (DAO) to Open Science and Open Access. Cincinnati, OH — April 11th, 2022 — Open Therapeutics, an open science company, announces its Chair and interim CEO, Jason E. Barkeloo, will lead an open science, open access, and DAO panel discussion at Devconnect Week, April 18th – April 25th, Beurs Van Berlage, Netherlands, entitled, “The Potential Impact of Decentralized Autonomous Organizations (DAO) to Open Science and Open Access”.

therapoid

Devconnect is an in-person gathering that will feature independent Ethereum blockchain events as part of ETHAmsterdam. Devconnect will host DeSci Day on April 20th, 2022, at the BOOM Theatre. The event will include talks, panels, pitches and demos from projects and leaders in the DeSci space, along with social events in the evening. Panel discussions will address the link between Decentralized Autonomous Organizations (DAOs), social impact, and scientific innovations.

Open Therapeutics’ mission is enabling the global research community to positively impact human, animal, plant, and global environmental health. Therapoid.net is its free open science platform for the public, researchers, and students. It provides grant funding, equipment, technologies, intellectual properties, forums, a manuscript review tool, and ScienceCoins cryptocurrency awards.

As scientists and students collaborate within the free Therapoid scientific platform, they gain ScienceCoins awards. One might think of ScienceCoins as “Bitcoin for scientists.”

For a limited time, when students and researchers freely register, they gain complimentary ScienceCoins.

According to Open Therapeutics founder, Jason E. Barkeloo, “I am proud to represent Open Therapeutics in its leadership of open science, and its support pillars of DeSci and open access, which are reaching a tipping point for global acceptance.”

This event is one of a future series of events to lead the open science, open access, and DeSci adoption.

* The complimentary ScienceCoins awards are available for only a limited time and are open to any qualified registrant.

About Open Therapeutics

The Company freely provides the scientific community the Therapoid™ platform; an open science collaboration ecosystem that puts scientists and students at the center of research for positively impacting human, animal, plant, and global environmental health. Therapoid freely provides technologies, intellectual properties (IP), grant funding, equipment, forums, manuscript review tool, career and academic opportunities, and ScienceCoins cryptocurrency awards. Through creating the world’s biggest think tank, members who openly share can be seen by recruiters for academic and career opportunities. This can be particularly beneficial to those in economically developing areas of Africa, Asia, and Latin America.

Media Contact:
Jason E. Barkeloo, Founder/Chair Open Therapeutics

https://Therapoid.net
Info@OpenTherapeutics.org
Twitter: twitter.com/OpenTherapeutic
LinkedIn: www.linkedin.com/company/10851290
Telegram: https://t.me/Therapoid